Abstract
Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in
Keywords: stroke, myocardial infarction, necrosis, apoptosis, blood vessels, inflammation, acute, chronic, drug development, dna repair
Current Vascular Pharmacology
Title: Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Volume: 3 Issue: 3
Author(s): Csaba Szabo
Affiliation:
Keywords: stroke, myocardial infarction, necrosis, apoptosis, blood vessels, inflammation, acute, chronic, drug development, dna repair
Abstract: Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in
Export Options
About this article
Cite this article as:
Szabo Csaba, Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions, Current Vascular Pharmacology 2005; 3 (3) . https://dx.doi.org/10.2174/1570161054368553
DOI https://dx.doi.org/10.2174/1570161054368553 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old
Cardiovascular & Hematological Agents in Medicinal Chemistry Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Diadenosine Polyphosphates: Postulated Mechanisms Mediating the Cardiac Effects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms of Action of Hypertonic Saline Resuscitation in Severe Sepsis and Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets A Rat Model of Ischemic Enteritis: Pathogenic Importance of Enterobacteria, iNOS/NO, and COX-2/PGE2
Current Pharmaceutical Design The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design